FORXIGA® (dapagliflozin)

FORXIGA® is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

FORXIGA®: Safety and tolerability

Results from an extensive clinical trial programme1

No increased risk of CV events with FORXIGA®43-45

In a meta-analysis of 21 Phase IIb/III studies, of 9,339 patients with a varying degree of CV risk and duration of T2D, FORXIGA® demonstrated:43-45*

  • No increased risk of CV events in the first 30 days following treatment initiation.43
  • Consistent CV safety profile in patients with established CVD.44
  • No increased risk of CV death or hospitalisation for heart failure (HR=0.70; 95% CI, 0.36 to 1.36 and HR=0.36; 95% CI, 0.16 to 0.84, respectively).43,45

A randomised trial to evaluate the effect of FORXIGA® on the incidence of cardiovascular events (DECLARE) is ongoing.46

eGFR mean change from baseline during treatment with FORXIGA
eGFR mean change from baseline during treatment with FORXIGA

*FORXIGA® is not indicated to reduce the risk of cardiovascular events.1